From Molecular Insights to Patient Stratification for Neurological and Psychiatric Disorders Proceedings of a Workshop (2022) / Chapter Skim
Currently Skimming:
Appendix B: Workshop Agenda
Appendix B: Workshop Agenda
Pages 77-84
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 77... ...
o Discuss the importance of improving existing biobanks and developing new biobanks in locations worldwide to reflect diverse populations.
|
From page 78... ...
. • Highlight lessons learned from recent advances in disorders asso ciated with rare, penetrant genetic variants, and explore how resulting lessons can be applied to more common neuropsychiatric disorders.
|
From page 79... ...
Key Discussion Questions: • What lessons have been learned from efforts aimed at enhanc ing ancestral diversity in genetic studies and biobanks, and what would move the field forward in a manner that is ethical and that advances strong partnerships when collaborating with disadvan taged populations and in low- and middle-income countries? • What are some effective approaches to including participants at risk and those in early stages of disease?
|
From page 80... ...
• How would greater ancestral diversity in genetic studies yield higher quality hypotheses and inform variant interpretation? 3:35pm Session Overview John Ngai, National Institutes of Health, Session Moderator 3:45pm Speakers Hilary Finucane, Massachusetts General Hospital; Harvard Medical School; Broad Institute of MIT and Harvard Jens Hjerling-Leffler, Karolinska Institutet Lea Starita, University of Washington Danielle Posthuma, VU Amsterdam Daniel Geschwind, University of California, Los Angeles 4:35pm Moderated Discussion with the Speakers and Q&A 4:55pm Day 1 Synthesis Steven Hyman, The Broad Institute of MIT and Harvard, Workshop Co-Chair Dimitri Krainc, Northwestern University, Workshop Co-Chair 5:00pm ADJOURN
|
From page 81... ...
• What criteria do different decision makers use when deciding how to validate biomarkers and select which targets to invest in and advance to clinic? 10:05am Session Overview Dimitri Krainc, Northwestern University, Workshop Co-Chair, Session Moderator 10:15am Speakers Helen Willsey, University of California, San Francisco Fenna Krienen, Harvard Medical School Paola Arlotta, Harvard University Martin Kampmann, University of California, San Francisco Daphne Koller, Insitro Alice Zhang, Verge Genomics
|
From page 82... ...
1:00pm Session Overview Linda Brady, National Institute of Mental Health, Session Moderator 1:10pm Speakers Charlotte Teunissen, Amsterdam UMC Danielle Graham, Biogen Pamela Horn, Food and Drug Administration Ernest Fraenkel, Massachusetts Institute of Technology Nikos Koutsouleris, Ludwig Maximilian University of Munich; King's College London 2:00pm Moderated Discussion with the Speakers and Q&A 3:15pm BREAK
|
From page 83... ...
Fox Foundation for Parkinson's Research Kafui Dzirasa, Duke University Carole Ho, Denali Henne Holstege, Amsterdam UMC John Ngai, National Institutes of Health Amir Tamiz, National Institute of Neurological Disorders and Stroke Stacie Weninger, FBRI 4:25pm Audience Q&A 4:55pm Acknowledgments and Concluding Remarks Steven Hyman, The Broad Institute of MIT and Harvard, Workshop Co-Chair Dimitri Krainc, Northwestern University, Workshop Co-Chair 5:00pm ADJOURN WORKSHOP
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.